| Treatment of lupus nephritis: facing the era of immunotherapy. | |
| | |
MedLine Citation:
|
PMID: 18927528 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting over half of SLE patients. The traditional treatment protocol with cyclophosphamide and corticosteroids dramatically improved patient and renal survival, but conferred a heavy burden of side effects. In addition, not all patients respond to first-line immunosuppression; 35% suffer at least one episode of renal relapse and 5-20% develop end-stage renal disease. Over the last decade, the increasing understanding of the complex pathogenesis underlying lupus nephritis and accelerating advances in molecular and cellular immunology have paved the way for development of immunomodulatory therapies for LN. In contrast to the global immunosuppressive effects of conventional treatment, these biologic agents target specific pathways that contribute to the inflammatory response, aiming to reduce tissue damage while preserving immunocompetence. The goal of this review is to highlight some of the more promising novel immunomodulators, including Abetimus sodium, Rituximab, Epratuzumab, Abatacept, Belimumab, Tocilizumab and Infliximab, and discuss how these agents affect central pathways in the pathogenesis of disease. |
| | |
Authors:
|
A A Aran; C Putterman |
Related Documents
:
|
20486908 - Visceral leishmaniasis in a kidney transplant recipient: parasitic interstitial nephrit... 11896888 - Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. 1902068 - T-pa, pai, and protein c before and after vascular occlusion of the upper limb in patie... 12955708 - De novo sle after cadaveric renal transplantation. 12789198 - Erythromelalgia precipitated by acral erythema in the setting of thrombocytopenia. 18778358 - Natural orifice translumenal endoscopic surgery (notes) renal cryoablation in a porcine... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Panminerva medica Volume: 50 ISSN: 0031-0808 ISO Abbreviation: Panminerva Med Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-10-17 Completed Date: 2009-01-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0421110 Medline TA: Panminerva Med Country: Italy |
Other Details:
|
Languages: eng Pagination: 235-45 Citation Subset: IM |
Affiliation:
|
Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY 10461, USA. aaran@aecom.yu.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
therapeutic use Antibodies, Monoclonal / therapeutic use Autoantibodies / biosynthesis B-Lymphocytes / drug effects, immunology Cytokines / antagonists & inhibitors Disease Progression Humans Immunosuppressive Agents / therapeutic use Immunotherapy* / adverse effects, methods Kidney Failure, Chronic / immunology, prevention & control* Lupus Nephritis / complications, immunology, therapy* Mesenchymal Stem Cell Transplantation Peripheral Blood Stem Cell Transplantation Recurrence T-Lymphocytes / drug effects, immunology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Autoantibodies; 0/Cytokines; 0/Immunosuppressive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pycnogenol may alleviate adverse effects in oncologic treatment.
Next Document: Is there a place for postmenopausal hormone therapy use in women with lupus?